Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

KIO-104

Phase 2Small molecule

KKiora Pharmaceuticals, Inc.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Macular EdemaRecruiting

Macular EdemaPhase 2

Recruiting

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Macular Edema

NCT06825702

Clinical

Trials by Indication[1]

Macular Edema1 trial

A Phase 2, Open-label, Multiple Dose Study of the Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema (KLARITY-1)

Recruiting·KKiora Pharmaceuticals, Inc.·Phase 2·NCT06825702·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for KIO-104. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KIO-104 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KIO-104. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kiora Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: KKiora Pharmaceuticals, Inc.

Related News